{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:56:15Z","timestamp":1773770175666,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["AG077700"],"award-info":[{"award-number":["AG077700"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), a phosphorylation kinase, is localized within the central nervous system and is linked to hyperphosphorylation of Tau. Imaging of DYRK1A may provide an earlier biomarker for Tauopathies, including Alzheimer\u2019s disease (AD). We have used Chimera-Autodock to evaluate potential molecules for binding to the binding site of DYRK1A. Five molecules, 10-bromo-2-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (4E3), 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (KuFal184), harmine, 6-(fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine (MK-6240), and 6-iodo-3-(1H-pyrrolo[2,3-c]pyridine-1-yl)isoquinoline (IPPI), were found to have binding energies of \u221210.4, \u221210.1, \u22129.0, \u22129.1, and \u22129.4 kcal\/mole, respectively. Two molecules, 4E3 and KuFal184, were selective for DYRK1A, while harmine also had a monoamine oxidase A affinity, and MK-6240 and IPPI had affinity for Tau. Tau present in the brain slices of AD subject were labeled with [125I]IPPI. KuFal184 had no effect on the binding of [125I]IPPI, suggesting the absence of binding overlap of the two molecules. MK-6240, a known Tau agent was, however, able to compete with [125I]IPPI. The binding energies of harmine, MK-6240, and IPPI for the DYRK1A site suggest affinities of approximately 80\u2013100 nM, which is insufficient to serve as an imaging agent. The higher affinity of KuFal184 (6 nM for DYRK1A) suggested that [125I]KuFal184 may be a potential imaging agent. Electrophilic radioiodination was used to synthesize [125I]KuFal184 in modest yields (25%) and high radiochemical purity (&gt;95%). Preliminary binding studies with [125I]KuFal184 in AD brain slices showed some selectivity for cortical grey matter regions containing Tau.<\/jats:p>","DOI":"10.3390\/molecules30050990","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:53:06Z","timestamp":1740124386000},"page":"990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7853-5335","authenticated-orcid":false,"given":"Cayz G.","family":"Paclibar","sequence":"first","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7817-7944","authenticated-orcid":false,"given":"Deanna M.","family":"Schafer","sequence":"additional","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0267-2299","authenticated-orcid":false,"given":"Agnes P.","family":"Biju","sequence":"additional","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3104-9523","authenticated-orcid":false,"given":"Fariha","family":"Karim","sequence":"additional","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1302-3219","authenticated-orcid":false,"given":"Stephanie A.","family":"Sison","sequence":"additional","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-294X","authenticated-orcid":false,"given":"Christopher","family":"Liang","sequence":"additional","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamiha T.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-877X","authenticated-orcid":false,"given":"Jogeshwar","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Preclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41380-023-02113-z","article-title":"Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer\u2019s disease? From clinical studies to the clinical trials","volume":"28","author":"Basheer","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","article-title":"Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging","volume":"2","author":"Therriault","year":"2002","journal-title":"Nat. Aging"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs. Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Rodriguez","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e14364","DOI":"10.1002\/alz.14364","article-title":"Blood biomarkers in Down syndrome: Facilitating Alzheimer\u2019s disease detection and monitoring","volume":"21","author":"Petersen","year":"2024","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Deboever, E., Fistrovich, A., Hulme, C., and Dunckley, T. (2022). The omnipresence of DYRK1A in human diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169355"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Atas-Ozcan, H., Brault, V., Duchon, A., and Herault, A. (2021). DYRK1A from gene function in development and physiology to dosage correction across life span in Down syndrome. Gene, 12.","DOI":"10.3390\/genes12111833"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"114062","DOI":"10.1016\/j.ejmech.2021.114062","article-title":"DYRK1A inhibitors for disease and therapy: Current status and perspectives","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00018-020-03626-4","article-title":"DYRK1A: A down syndrome-related dual protein kinase with a versatile role in tumorigenesis","volume":"78","author":"Laham","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1096\/fj.07-104539","article-title":"Overexpression of DYRK1A contributes to neurofibrillary degeneration in Down syndrome","volume":"22","author":"Liu","year":"2008","journal-title":"FASEB J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41388-022-02245-6","article-title":"The chromosome 21 kinase DYRK1A: Emerging roles in cancer biology and potential as a therapeutic target","volume":"41","author":"Rammohan","year":"2022","journal-title":"Oncogene"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","article-title":"DYRK1A-mediated hyperphosphorylation of Tau","volume":"282","author":"Ryoo","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jnr.23279","article-title":"Intracellular distribution of differentially phosphorylated dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A)","volume":"92","author":"Kaczmarski","year":"2014","journal-title":"J. Neurosci Res."},{"key":"ref_18","first-page":"3131","article-title":"Crystal structure of DYRK1AA in complex with 10-bromo-substituted 11H-indolo [3,2-c]quinolone-6-carboxylic acid inhibitor 5t","volume":"58","author":"Chaikaud","year":"2015","journal-title":"Protein Data Bank"},{"key":"ref_19","first-page":"e56","article-title":"Development of covalent inhibitors: Principle, design, and application in cancer","volume":"2","author":"Zheng","year":"2023","journal-title":"Med. Comm. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105821","DOI":"10.1016\/j.ejps.2021.105821","article-title":"Identification of harmine and b-carboline analogs from a high throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies","volume":"162","author":"Tarpley","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/jm501994d","article-title":"10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A","volume":"58","author":"Falke","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Shukla, R., Kumar, A., Kelvin, D.J., and Singh, T.R. (2022). Disruption of DYRK1A-induced hyperphosphorylation of amyloid beta and tau protein in Alzheimer\u2019s disease: An integrative molecular modeling approach. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1078987"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Meine, R., Becker, W., Falke, H., Preu, L., Loa\u00ebc, N., Meijer, L., and Kunick, C. (2018). Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design. Molecules, 23.","DOI":"10.3390\/molecules23020064"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrd2111","article-title":"Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases","volume":"6","author":"Mazanetz","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e22183","DOI":"10.1002\/syn.22183","article-title":"Development and evaluation [125I]IPPI for tau imaging in post-mortem human Alzheimer\u2019s disease brain","volume":"74","author":"Mukherjee","year":"2021","journal-title":"Synapse"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mondal, R., Sandhu, Y.K., Kamalia, V.M., Delaney, B.A., Syed, A.U., Nguyen, G.A.H., Moran, T.R., Limpengco, R.R., Liang, C., and Mukherjee, J. (2023). Measurement of Ab amyloid and Tau protein in postmortem human Alzheimer\u2019s disease brain by autoradiography using [18F]flotaza, [125I]IBETA and [124\/125I]IPPI and immunohistochemistry analysis using QuPath. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041033"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/cmdc.201600539","article-title":"Structure-based design and synthesis of harmine derivatives with different selectivity profiles in kinase versus monoamine oxidase inhibition","volume":"12","author":"Balint","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3390\/neurolint16020031","article-title":"[125I]IPC-Lecanemab: Synthesis and evaluation of Ab-plaque-binding antibody and comparison with small-molecule [18F]Flotaza and [125I]IBETA in postmortem human Alzheimer\u2019s disease","volume":"16","author":"Liang","year":"2024","journal-title":"Neurol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2967\/jnumed.115.171678","article-title":"Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles","volume":"57","author":"Hostetler","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Limpengco, R.R., Liang, C., Sandhu, Y.K., and Mukherjee, J. (2023). [125I]INFT: Development and Evaluation of a new Tau Imaging agent in Post-Mortem Human Alzheimer\u2019s disease brain. Molecules, 28.","DOI":"10.3390\/molecules28155769"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Nguyen, G.A.H., Liang, C., and Mukherjee, J. (2022). [124I]IBETA, a new Ab amyloid plaque PET imaging agent for Alzheimer\u2019s disease. Molecules, 27.","DOI":"10.3390\/molecules27144552"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sison, S.A., Paclibar, C.G., Liang, C., and Mukherjee, J. (2024). Radioiodinated tau imaging agent III molecular modeling, synthesis, and evaluation of a new tau imaging agent, [125I]ISAS in post-mortem human Alzheimer\u2019s disease brain. Molecules, 29.","DOI":"10.3390\/molecules29143308"},{"key":"ref_33","first-page":"13122","article-title":"Increasing membrane permeability of carboxylic acid-containing drugs using synthetic transmembrane anion transporters","volume":"57","author":"Salam","year":"2021","journal-title":"ChemComm"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer\u2019s disease age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/j.semnuclmed.2023.03.004","article-title":"Preclinical evaluation of novel PET probes for dementia","volume":"53","author":"Cools","year":"2023","journal-title":"Sem. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cao, L., Kong, Y., Ji, B., Ren, Y., Guan, Y., and Ni, R. (2021). Positron emission tomography in animal models of taupathies. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.761913"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.121.263196","article-title":"Tau PET imaging in neurodegenerative disorders","volume":"63","author":"Groot","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Shah, N., Ghazaryan, N., Gonzaga, N.L., Paclibar, C.G., Biju, A.P., Liang, C., and Mukherjee, J. (2024). Glutamate\u2019s effects on the N-methyl-D-aspartate (NMDA) receptor ion channel in Alzheimer\u2019s disease brain: Challenges for PET radiotracer development for imaging the NMDA ion channel. Molecules, 29.","DOI":"10.3390\/molecules29010020"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Syed, A.U., Liang, C., Patel, K.K., Mondal, R., Kamalia, V.M., Moran, T.R., Ahmed, S.T., and Mukherjee, J. (2023). Comparison of Monoamine oxidase-A, Ab plaques, Tau and Translocator protein in postmortem human Alzheimer\u2019s disease brain. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310808"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sandhu, Y.K., Bath, H.S., Shergill, J., Liang, C., Syed, A.U., Ngo, A., Karim, F., Serrano, G.E., Beach, T.G., and Mukherjee, J. (2024). [18F]Flotaza for A\u03b2 plaque diagnostic imaging: Evaluation in postmortem human Alzheimer\u2019s disease brain hippocampus and PET\/CT imaging in 5xFAD transgenic mice. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147890"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11307-018-1165-3","article-title":"[11C]Harmine binding to brain monoamine oxidase A: Test-retest properties and noninvasive quantification","volume":"20","author":"Zanderigo","year":"2018","journal-title":"Mol. Imag. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.3233\/JAD-240078","article-title":"Leucettinib-21, a DYRK1A kinase inhibitor as clinical drug candidate for Alzheimers disease and Down syndrome","volume":"101","author":"Meijer","year":"2024","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/mgg3.334","article-title":"Targeting trisomic treatments: Optimizing Dyrk1a inhibition to improve Down syndrome deficits","volume":"5","author":"Stringer","year":"2017","journal-title":"Mol. Genet. Genom. Med."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/5\/990\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:19Z","timestamp":1760027959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/5\/990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["molecules30050990"],"URL":"https:\/\/doi.org\/10.3390\/molecules30050990","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}